Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurrent Miscarriage

NACompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

November 30, 1999

Primary Completion Date

March 31, 2009

Study Completion Date

January 31, 2010

Conditions
Miscarriage, RecurrentAbortion, Habitual
Interventions
BIOLOGICAL

Gamimune N or Gamunex 10%

500 mg/kg administered in the follicular phase of the menstrual cycle. With conception, infusions every four weeks until 18-20 weeks of gestation.

OTHER

normal saline

equivalent volume of normal saline

Trial Locations (1)

60637

The University of Chicago, Chicago

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

University of British Columbia

OTHER

collaborator

University of Tennessee

OTHER

collaborator

Sunnybrook Health Sciences Centre

OTHER

collaborator

Grifols Therapeutics LLC

INDUSTRY

lead

University of Chicago

OTHER